Leucine modulates the effect of Walker factor, a proteolysis-inducing factor-like protein from Walker tumours, on gene expression and cellular activity in C2C12 myotubes

Cytokine

Volumn 64, Issue 1, 2013, Pages 343-350

  Gonçalves, Estela Maria ^a   Salomão, Emilianne Miguel ^a   Gomes Marcondes, Maria Cristina Cintra ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cancer cachexia; Leucine; Proteolysis inducing factor; Walker 256 tumour; Walker factor

Indexed keywords

ALKALINE PHOSPHATASE; CATHEPSIN B; CHYMOTRYPSIN; CYTOKINE; LEUCINE; PROTEASOME; UNCLASSIFIED DRUG; WALKER FACTOR;

20S PROTEASOME GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN C2C12; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; MALE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; WALKER CARCINOMA;

ANIMALIA; RATTUS;

CANCER CACHEXIA; LEUCINE; PROTEOLYSIS-INDUCING FACTOR; WALKER 256 TUMOUR; WALKER FACTOR;

ALKALINE PHOSPHATASE; ANIMALS; CACHEXIA; CARCINOMA 256, WALKER; CATHEPSIN B; CELL SURVIVAL; CHYMOTRYPSIN; GENE EXPRESSION; LEUCINE; MALE; MUSCLE FIBERS, SKELETAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEOGLYCANS; PROTEOLYSIS; RATS; RATS, WISTAR;

EID: 84883553872     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.05.018     Document Type: Article

References (63)

1. Boddaert M.S.A., Gerritsen W.R., Pinedo H.M. On our way to targeted therapy for cachexia in cancer?. Curr Opin Oncol 2006, 18:335-340.
2. Fearon K.C.H. The mechanism and treatment of weight loss in cancer. Proc Nutr Soc 1992, 51:251-265.
3. Costelli P., Baccino F.M. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 2003, 6:407-412.
4. De Wys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980, 69:491-497.
5. Windsor J.A., Hill G.L. Risk factors for postoperative pneumonia. The importance of protein depletion. Ann Surg 1988, 208:209-214.
6. Tisdale M.J. Protein loss in cancer cachexia. Science 2000, 289:2293-2294.
7. Tisdale M.J. Cachexia in cancer patients. Nature 2002, 2:862-870.
8. Tisdale M.J. Biology of cachexia. J Nat Cancer Inst 1997, 89:1763-1773.
9. Tisdale M.J. Isolation of a novel cancer cachectic factor. Proc Nutr Soc 1997, 56:777-783.
10. Todorov P., Deacon M., Tisdale M.J. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997, 272:12279-12288.
11. Lorite M.J., Smith H.J., Arnold J.A., Morris A., Thompson M.G., Tisdale M.J. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001, 85:297-302.
12. Busquets S., Alvarez B., Lopez-Soriano F.J., Argiles J.M. Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. J Cell Physiol 2002, 19:283-289.
13. Ventrucci G., Mello M.A.R., Gomes-Marcondes M.C.C. Proteasome activity is altered in skeletal muscle tissue of tumour-bearing rats fed a leucine-rich diet. Endocr Relat Cancer 2004, 11:887-895.
14. Gomes-Marcondes M.C.C., Ventrucci G., Toledo M.T., Cury L., Cooper J.C. A leucine-supplemented diet improved protein content of skeletal muscle in young tumor-bearing rats. Braz J Med Biol Res 2003, 36:1589-1594.
15. Ventrucci G., Mello M.A.R., Gomes-Marcondes M.C.C. Leucine-rich diet alters the eukaryotic translation initiation factors expression in skeletal muscle of tumour-bearing rats. BMC Cancer 2007, 7:42.
16. Gomes-Marcondes M.C.C., Honma H.N., Areas M.A., Cury L. Effect of walker 256 tumour growth on intestinal absorption of leucine methionine and glucose in newly weaned and mature rats. Braz J Med Biol Res 1998, 31:1345-1348.
17. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
18. Todorov P., Cariuk P., Mc Devitt T., Coles B., Fearon K.C., Tisdale M.J. Characterization of a cancer cachectic factor. Nature 1996, 22:739-742.
19. Yano C.L., Ventrucci G., Field W.N., Tisdale M.J., Gomes-Marcondes M.C.C. Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes. BMC Cancer 2008, 8:24.
20. Rosen H. A modified ninhydrin colorimetric analysis for amino acids. Arch Biochem Biophys 1957, 67:10-15.
21. Murakami N., Fukuchi S., Takeuchi K., Hori T., Shibamoto S., Ito F. Antagonistic regulation of cell migration by epidermal growth factor and glucocorticoid in human gastric carcinoma cells. J Cell Physiol 1998, 176:127-136.
22. Orino E., Tanaka K., Tamura T., Sone S., Ogura T., Ichihara A. ATP-dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubiquitinated proteins in human HL-60 cells. FEBS Lett 1991, 284:206-210.
23. Lowry O., Rosebrough N.J., Farr A.L., Randall R.L. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
24. Barrett A.J. Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J 1980, 187:909-912.
25. Jiang S.-T., Wang J.-H., Chang T., Chen C.-S. A continuous method for measuring calpain activity. Analyt Biochem 1997, 244:233-238.
26. Martins M.J., Negrão M.R., Hipólito-Reis C., Azevedo I. Arginine and a polyarginine peptide inhibit alkaline phosphatase activity: possible consequences for cellular transport systems. Clin Biochem 2001, 34:435-437.
27. White M.E., Allen C.E., Dayton W.R. Effect of sera from fed and fasted pigs on proliferation and protein turnover in cultured myogenic cells. J Anim Sci 1988, 66:34-42.
28. Gomes-Marcondes M.C., Smith H.J., Cooper J.C., Tisdale M.J. Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer 2002, 86:1628-1633.
29. Jeevanandam M., Lowry S.F., Horowitz G.D., Brennan M.F. Cancer cachexia and protein metabolism. Lancet 1984, 1:1423-1426.
30. Tisdale M.J. Cancer anorexia and cachexia. Nutrition 2001, 17:438-442.
31. Tisdale M.J. Mechanism of cancer cachexia. Physiol Rev 2009, 89:381-410.
32. Belizario J.E., Katz M., Chenker E., Raw I. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 1991, 63:705-710.
33. Tisdale M.J. New cachexic factors. Curr Opin Clin Nutr Metab Care 1998, 1:253-256.
34. Tisdale M.J. Are tumoral factors responsible for host tissue wasting in cancer cachexia?. Future Oncol 2010, 6:503-513.
35. Deans D.A.C., Wigmore S.J., Gilmour H., Tisdale M.J., Fearon K.C.H., Ross J.A. Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy. Br J Cancer 2006, 94:731-736.
36. Ventrucci G., Mello M.A.R., Gomes-Marcondes M.C.C. Effects of leucine supplemented diet on intestinal absorption in tumor bearing pregnant rats. BMC Cancer 2002, 2:7.
37. Emery P.W. Cachexia in experimental models. Nutrition 1999, 15:600-603.
38. Han B., Tong J., Zhu M.J., Ma C., Du M. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway. Mol Reprod Dev 2007, 10.1002/mrd.20832.
39. Erbay E., Park I.H., Nuzzi P.D., Schoenherr C.J., Chen J. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 2003, 163:931-936.
40. Wang X., Proud C.G. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006, 21:362-369.
41. Wang X., Proud C.G. Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol 2009, 19:260-267.
42. Park I.H., Erbay E., Nuzzi P., Chen J. Skeletal myocyte hypertrophy requires mTOR kinase activity and S6 K1. Exp Cell Res 2005, 309:211-219.
43. Nader G.A., McLoughlin T.J., Esser K.A. MTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators. Am J Physiol Cell Physiol 2005, 289:C1457-C1465.
44. Combaret L., Dardevet D., Béchet D., Taillandier D., Mosoni L., Attaix D. Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care 2009, 12:37-41.
45. Liao Y., Hung M.C. Physiological regulation of Akt activity and stability. Am J Transl Res 2010, 2:19-42.
46. Lecker S.H., Solomon V., Mitch W.E., Goldberg A.L. Muscle protein breakdown and critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999, 129:227S-237S.
47. Bechet D., Tassa A., Taillandier D., Combaret L., Attaix D. Lysosomal proteolysis in skeletal muscle. Inter J Biochem Cell Biol 2005, 37:2098-2114.
48. Goll D.E., Thompson V.F., Taylor R.G., Christiansen J.A. Role of the calpain system in muscle growth. Biochimie 1992, 74:225-237.
49. Goll D.E., Neti G., Mares S.W., Thompson V.F. Myofibrillar protein turnover: the proteasome and the calpains. J Anim Sci 2008, 86:E19-E35.
50. Kornitzer D., Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol 2000, 182:1-11.
51. Béchet D., Tassa A., Combaret L., Taillandier D., Attaix D. Regulation of skeletal muscle proteolysis by amino acids. J Renal Nutr 2005, 15:18-22.
52. Bossola M., Muscaritoli M., Costelli P., Grieco G., Bonelli G., Pacelli F., et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003, 237:384-389.
53. Khal J., Hine A.V., Fearon K.C.H., Dejong C.H.C., Tisdale M.J. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005, 37:2196-2206.
54. Williams A., Sun X., Fischer J.E., Hasselgren P.O. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999, 126:744-750.
55. Khal J., Wyke S.M., Russell S.T., Hine A.V., Tisdale M.J. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 2005, 93:774-780.
56. Lorite M.J., Thompson M.G., Drake J.L., Carling G., Tisdale M.J. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998, 78:850-856.
57. Dardevet D., Sornet C., Belage M., Grizard J. Stimulation of in vitro rat muscle protein synthesis by leucine decreases with age. J Nutr 2000, 130:2630-2635.
58. Drummond M.J., Rasmussen B.B. Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. Curr Opin Clin Nutr Metab Care 2008, 11:222-226.
59. Nicastro H., Artioli G.G., Costa Ados S., Solis M.Y., da Luz C.L., Blachier F., et al. An overview of the therapeutic effects of leucine supplementation on skeletal muscle under atrophic conditions. Amino Acids 2010, 10.1007/s00726-010-0636-x.
60. Kettelhut I.C., Wing S.S., Goldberg A.L. Endocrine regulation of protein breakdown in skeletal muscle. Diabetes Metabol Rev 1988, 4:751-772.
61. Yoshizawa F., Kimball S.R., Vary T.C., Jefferson L.S. Effect of dietary protein on translation initiation in rat skeletal muscle and liver. Am J Physiol 1998, 275:E814-E820.
62. Anthony J.C., Reiter A.K., Anthony T.G., Crozier S.J., Lang C.H., MacLean D.A., et al. Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E-BP1 or S6K1 phosphorylation. Diabetes 2002, 51:928-936.
63. Proud C.G. Amino acids and mTOR signalling in anabolic function. Biochem Soc Trans 2007, 35:1187-1190.